Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BULLETIN
October 27, 2003
- DIAGNOSTIC NEWS IN BRIEF
October 27, 2003
- WEBSITE NEWS
October 27, 2003
- Most GE Houses Forecast Growth in FY2003: EPMA Survey
October 27, 2003
- ＜Special Contribution＞
October 27, 2003
- Import Approval for Evista, Precedex Recommended
October 27, 2003
- Pricing of Long-listed Drugs Discussed by Chuikyo Subpanel
October 27, 2003
- Korosho to Widen Selection Criteria for Priority NDA Review
October 27, 2003
- REGULATORY NEWS IN BRIEF
October 27, 2003
- Developing Something Like a Niche: Dr Matsuda of Kyowa Hakko
October 27, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 27, 2003
- WORLD NEWS IN BRIEF
October 27, 2003
- WEBSITE NEWS
October 27, 2003
- Taiyo Expects Strong Growth in Contract Manufacturing Business
October 27, 2003
- Semiannual Business Results
October 27, 2003
- Kyorin Is Pursuing 4 Scenarios for Independent Marketing in US
October 27, 2003
- Fujisawa, Yamanouchi to Merge OTC Drug Businesses
October 27, 2003
- BULLETIN
October 27, 2003
- Taisho to Be Exclusive Sales Agent for P&G's Vicks VapoRub
October 27, 2003
- Wholesalers' FY2003 Results Could Be Worse than FY2001's: Mr Kimura
October 27, 2003
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…